In November 2011, ruxolitinib (Jakafi; Incyte/Novartis), a small-molecule inhibitor of Janus kinases, was approved by the US Food and Drug Administration for the treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis.
|Original language||English (US)|
|Number of pages||2|
|Journal||Nature Reviews Drug Discovery|
|State||Published - Feb 1 2012|
ASJC Scopus subject areas
- Drug Discovery